Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major…

FDA Green Lights Novel Oral GLP-1 Drug with 10X Better Exposure Than Competitors

New oral GLP-1 shows 10X higher exposure vs competitors in trials. Phase 1 studies start 2H 2025 for obesity treatment. Get the clinical timeline.